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Abstract: Staphylococcus aureus causes many types of infections, ranging from self-resolving skin
infections to severe or fatal pneumonia. Human innate immune cells, called polymorphonuclear
leukocytes (PMNs or neutrophils), are essential for defense against S. aureus infections. Neutrophils
are the most prominent cell type of the innate immune system and are capable of producing
non-specific antimicrobial molecules that are effective at eliminating bacteria. Although significant
progress has been made over the past few decades, our knowledge of S. aureus-host innate immune
system interactions is incomplete. Most notably, S. aureus has the capacity to produce numerous
molecules that are directed to protect the bacterium from neutrophils. Here we review in brief the role
played by neutrophils in defense against S. aureus infection, and correspondingly, highlight selected
S. aureus molecules that target key neutrophil functions.
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1. Introduction
Staphylococcus aureus is adept at circumventing destruction by the human innate immune system,
and the bacterium imposes a significant disease burden on at-risk and otherwise healthy populations
worldwide [1]. S. aureus commonly resides as a quiescent commensal within the human nares, and,
as such, is a frequent cause of opportunistic infections [2]. Indeed, S. aureus has remained a leading
cause of healthcare and community associated infections in the United States over the past 60 years.
The organism causes a broad array of diseases and syndromes, such as endocarditis, toxic-shock
syndrome, bacteremia, soft-tissue infections, surgical-site infections, and pneumonia [3–6]. In addition,
the pathogen is notorious for its ability to acquire antibiotic resistance, and S. aureus increasingly
undermines treatment regimens already hampered by a substantial lack of novel therapeutics [7,8].
Taken together, the propensity for S. aureus to develop antibiotic resistance and cause significant
morbidity, underscores the importance of developing new therapeutic approaches for treatment
of infections.
Polymorphonuclear leukocytes (PMNs or neutrophils) are the most prominent cellular component
of the host innate immune response to bacterial and fungal infections. The vast majority of healthy
individuals are seemingly protected against severe S. aureus infections, and this characteristic is
attributed largely to the role played by neutrophils in host defense. Indeed, individuals with neutrophil
defects are highly susceptible to severe and life-threatening S. aureus infections [9]. This review
highlights the role of neutrophils in innate immunity, and specific mechanisms used by S. aureus to
circumvent elimination by PMNs.
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2. Neutrophils in Host Defense
Neutrophils are the primary cellular constituent of the human innate immune system and are
essential for host defense against invading microbial pathogens. PMNs originate and mature in
the bone marrow, and are subsequently released into the peripheral vasculature. High numbers of
neutrophils are maintained in circulation to facilitate rapid recruitment to infected tissue. Intravascular
circulating neutrophils comprise approximately half of the entire granulocyte population, whereas
marginated neutrophils maturing in the bone marrow or resident in organ systems make up the
remaining half [10,11]. Mature neutrophils enter the vasculature from the bone marrow at a rate of
approximately 109 cells/kg body weight every day in a healthy human adult [10,11]. Circulating
neutrophils, by sheer force of presence, are poised for recruitment by chemotactic signals to areas
of infection. The large pool of circulating PMNs is available to support the inflammatory response
to infection.
Circulating neutrophils are recruited to infection sites through chemotactic signals produced by
host cells and shed and/or secreted bacterial molecules. The ability of neutrophils to rapidly respond
to invading microorganisms is a key facet of innate immunity. Neutrophils are highly sensitive to
chemotactic signals that signify infection and promote migration. Host-derived chemotactic factors,
such as interleukin 8, GRO-alpha, granulocyte chemotactic protein 2, and complement component
C5a are potent proinflammatory mediators that are used to recruit additional PMNs to areas of
infection [12–14]. Further, PMN migration can be elicited directly or indirectly by bacteria-derived
stimuli, such as lipoteichoic acid or n-formyl peptides [15–20]. At sites of infection, a diversity of
resident cells contribute to production of chemotactic factors including macrophages, endothelial, and
epithelial cells [21–23].
Neutrophil recruitment from the bloodstream to infected tissue is governed by a series of complex
signal transduction cascades that ultimately control the dynamics of PMN interaction with vascular
cells and regulate chemotaxis [12,13]. The neutrophil recruitment process can be broken into four steps:
Rolling adhesion, integrin activation, firm adhesion, and transmigration. PMN recruitment is initiated
by inflammatory mediators, and is followed by the expression of surface ligands on the neutrophil
plasma membrane [12,13,24]. During rolling adhesion, PMNs travel through the bloodstream by
shear force within blood vessels, adherence to the blood vessel walls is maintained by repetitive
ligand-receptor binding mediated by selectins allowing for reversible and bidirectional modulation of
the binding process of neutrophils to endothelial cells [12,13,24]. Neutrophil-endothelial cell (blood
vessel) adhesion interactions–mediated by expression of lymphocyte function-associated antigen-1
(LFA-1)–shift to a higher affinity state following stimulation by proinflammatory mediators. LFA-1
binds to intracellular adhesion molecule (ICAM)-1 and ICAM-2 present on endothelial cells, resulting
in neutrophil arrest [13,24]. LFA-1 integrin clustering on the neutrophil plasma membrane increase the
avidity of the binding process and stimulates cytoskeletal/receptor rearrangements that induce PMN
morphological changes [24]. As the PMN morphology shifts from spherical to flat, shear force is no
longer capable of initiating neutrophil movement through the blood vessel [12,13]. Following firm
attachment to the endothelium, neutrophil transmigration from the endothelium into infected tissue is
facilitated by several leukocyte and endothelial cell molecules including CD31, CD11b/CD18, CD47,
and CD44 [12,13].
Neutrophils play a primary role in host defense and remove pathogens through a process known
as phagocytosis. Phagocytosis is initiated by recognition and binding of bacteria, and is followed by
internalization. Recognition of microbial pathogens is determined by pattern recognition receptors
(PRRs) and opsonin receptors. PRRs bind microbe-associated molecules known as pathogen-associated
molecular patterns (PAMPs), and PRRs are an essential component of the host-immune surveillance.
The composition of PRRs includes a broad array of receptors, such as membrane-bound toll-like
receptors (TLRs), that identify highly conserved bacterial surface and secreted molecules. PRR
ligation induces intracellular signal transduction cascades that trigger enhanced phagocytosis and
cytokine production, albeit pathogen recognition by PRRs alone is generally insufficient to stimulate
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phagocytosis [25–27]. The efficiency of phagocytosis is enhanced when invading microorganisms are
opsonized with host serum molecules such as complement and antibody. Specific IgG, when bound
to microbial surfaces, directs the deposition of serum complement. Distinct IgG and complement
receptors on the neutrophil directly mediate uptake of opsonized microbes [28,29] (Figure 1).
Fc receptor binding leads to the induction of highly complex signal transduction cascades that direct
membrane reorganization, actin polymerization, and cytoskeletal rearrangements that are essential
for phagocytosis. Electrophysiological alterations in transmembrane potential elicit lipid signaling
cascades and actin polymerization that contribute to the advancing membrane cup. Complete microbial
engulfment is accomplished when the membrane cup entirely surrounds the pathogen and closes to
form a nascent phagosome.
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NADPH-dependent oxidase on PMN phagosomes [30–32]. The NADPH oxidase complex generates 
high levels of reactive oxygen species (ROS) in activated neutrophils [32,33]. The NADPH oxidase 
functions by shuttling electrons across the phagosomal membrane from cytosolic NADPH to 
intraphagosomal molecular oxygen to produce O2−. The superoxide anion is readily converted to 
hydrogen peroxide by superoxide dismutase. Notably, hydrogen peroxide and other secondary 
oxygen derivatives such hydroxyl radical, chloramines and hypochlorous acid (HOCl), which is 
generated by the myeloperoxidase-halide system, contribute to PMN microbicidal activity [33,34]. 
Neutrophil oxygen-independent microbicidal activity is effected by numerous degradative enzymes 
and cationic peptides contained in granules (primary, secondary, and tertiary) and secretory vesicles. 
Following phagocytosis, granules are trafficked to and fuse with PMN phagosomes in a process 
called degranulation [35–37]. Although the composition of granules varies by type, collectively they 
enrich the vacuole lumen with microbicidal agents such as cathepsins, elastase, proteinase-3, 
defensins, lysozyme, azurocidin and bacterial permeability increasing protein [35,36,38]. Collectively, 
PMN oxygen-dependent and oxygen-independent microbicidal systems are highly efficient for 
elimination of invading bacterial pathogens.  
Figure 1. eutrophil phagocytosis of S. aureus. S. aureus opsonized with serum complement
components (complement) and specific antibody (antibody) are efficiently bound by complement
receptors and Fc receptors on the surface of neutrophils. Ligation of these receptors drives the process
of phagocytosis.
Neutrophils use both oxygen-dependent and oxygen-independent processes to kill invading
microbial pathogens (Figure 2). Phagocytosis of bacteria triggers assembly of a membrane-bound
NADPH-dependent oxidase on PMN phagosomes [30–32]. The NADPH oxidase complex generates
high levels of reactive oxygen species (ROS) in activated neutrophils [32,33]. The NADPH oxidase
functions by shuttling electrons across the phagosomal membrane from cytosolic NADPH to
intraphagosomal molecular oxygen to produce O2´. The superoxide anion is readily converted
to hydrogen peroxide by superoxide dismutase. Notably, hydrogen peroxide and other secondary
oxygen derivatives such hydroxyl radical, chloramines and hypochlorous acid (HOCl), which is
generated by the myeloperoxidase-halide system, contribute to PMN microbicidal activity [33,34].
Neutrophil oxygen-independent microbicidal activity is effected by numerous degradative enzymes
and cationic peptides contained in granules (primary, secondary, and tertiary) and secretory vesicles.
Following phagocytosis, granules are trafficked to and fuse with PMN phagosomes in a process called
degranulation [35–37]. Although the composition of granules varies by type, collectively they enrich
the vacuole lumen with microbicidal agents such as cathepsins, elastase, proteinase-3, defensins,
lysozyme, azurocidin and bacterial permeability increasing protein [35,36,38]. Collectively, PMN
oxygen-dependent and oxygen-independent microbicidal systems are highly efficient for elimination
of invading bacterial pathogens.
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3.1. Inhibition of Neutrophil Recruitment
Chemotaxis inhibiting protein of S. aureus (CHIPS) is a freely secreted protein that inhibits
neutrophil and monocyte chemotaxis [43,44]. CHIPS binds directly to the C5a and formyl peptide
receptors (FPRs), and thereby inhibits phagocyte recruitment [44]. The gene encoding CHIPS, along
with those for 3 other immune evasion molecules—staphylococcal complement inhibitor (SCIN),
staphylokinase (SAK), and S. aureus enterotoxin A or P (SEA or SEP)—is located on a mobile genetic
element known as a β-hemolysin-converting bacteriophage [45]. SAK binds and inhibits the ability of
neutrophil defensins to kill bacteria [46], and SEA or SEP are superantigens with known capacity to
modulate phagocyte function [47–49]. Collectively, the genes encoding these molecules comprise an
immune evasion cluster (IEC) that is present in many S. aureus strains tested to date [45]. More recently,
Stapels et al. reported that S. aureus extracellular adherence protein (Eap) and two homologs, EapH1
and EapH2, inhibit neutrophil elastase, proteinase-3, and cathepsin G [50]. These neutrophil serine
proteases can cleave S. aureus immune evasion molecules, such as SCIN and CHIPS, and this process is
blocked by the Eap molecules [51]. The extent to which these molecules contribute to pathogenesis in
humans remains to be determined.
There is also a family of staphylococcal-like proteins (Ssls) that has been reported to function
as immune evasion molecules. For example, Ssl7 binds host IgA and complement component C5,
inhibiting generation of C5a, phagocytosis, and production of phagocyte reactive oxygen species [52,53].
In addition, Bestebroer et al. found that Ssl7 blocked neutrophil recruitment in a mouse model of
inflammation [52]. This same research group reported Ssl5 associates with P-selectin glycoprotein
ligand-1 (PSGL-1, also known as CD162) and inhibits neutrophil rolling in vitro [54]. In subsequent
studies, they demonstrated Ssl5 bound the amino terminus G protein-coupled receptors, thereby
inhibiting leukocyte activation by host inflammatory molecules such as cytokines [55].
S. aureus produces at least five molecules that inhibit serum complement convertases—host
enzyme complexes important for a fully functional complement system. The activity of host C3
convertase is essential for the opsonization of microbes with complement components such as C3b and
iC3b, which promote phagocytosis by complement receptors. Moreover, activation of the complement
system ultimately generates C5a, a neutrophil chemoattractant. Staphylococcal complement inhibitor
(SCIN) and homologues (SCIN–B and SCIN–C), extracellular fibrinogen-binding protein (Efb), and
extracellular complement-binding protein (Ecb), bind and inhibit the C3 convertase (SCIN proteins),
or alternatively, C3b–containing convertases and C5 convertases (Efb and Ecb) [56,57]. The interaction
of these S. aureus molecules with the host complement system inhibits leukocyte recruitment and
neutrophil phagocytosis of S. aureus in vitro and ex vivo in human blood [58,59]. Although SCIN and
homologues are human-specific, and thus cannot be tested effectively in animal infection models, Efb
has been shown to inhibit phagocytosis of S. aureus in a mouse infection model [59]. The ability of Efb
to block phagocytosis is independent of its ability to inhibit complement. Rather, Efb forms a complex
with fibrinogen and C3b on the microbe surface, and in doing so blocks phagocytosis [59]. Jongerius et
al. found that SCIN-B, SCIN-C, Efb and Ecb are located within a segment of the S. aureus genome that
also encodes alpha-hemolysin (Hla), Ssl12, Ssl13, Ssl14, FPR-like 1 inhibitory protein (FLIPr), and a
FLIPr homologue (FLIPr-like) [57]. Inasmuch as these genes contribute to S. aureus evasion of host
defense, this segment of the genome was named immune evasion cluster 2 (IEC-2) [57].
Laarman et al. recently demonstrated that staphopain A (ScpA), a secreted S. aureus cysteine
protease, inhibits in vitro neutrophil chemotaxis mediated by CXCR2 [60]. ScpA cleaves an N-terminal
region of CXCR2, and this phenomenon blocks signal transduction triggered by key proinflammatory
chemokines such as IL-8 and GROα [60]. The redundancy of molecules directed to inhibit neutrophil
chemotaxis and complement activation is curious, especially for a commensal microbe that infrequently
causes severe infections in otherwise healthy individuals.
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3.2. Inhibition of Phagocytosis?
In addition to the complement inhibitors discussed above, several other S. aureus molecules have
been shown to inhibit neutrophil phagocytosis in vitro or in whole blood. For instance, S. aureus protein
A (SpA) and the second binding protein of immunoglobulin (Sbi) associate with the Fc-region of
immunoglobulin and can inhibit phagocytosis in vitro [61–64]. S. aureus capsule polysaccharide [65,66],
clumping factor A [67], and iron-regulated surface determinant protein H (IsdH) [68], have also
been shown to inhibit S. aureus phagocytosis in vitro. S. aureus strains lacking at least two of these
molecules—e.g., those lacking Spa and ClfA—are ingested to a greater extent by neutrophils than
those lacking only one of these molecules [67]. It is noteworthy that none of these molecules, either
singly or collectively, inhibit in vitro uptake by neutrophils completely. The ability of these molecules
to block uptake is also probably dependent on assay conditions. The vast majority of the studies of
S. aureus phagocytosis by neutrophils have been performed with cells in suspension. The extent to
which phagocytosis assays with neutrophils in suspension approximate the interaction of bacteria
with neutrophils in the bloodstream is unclear. It has long been known that neutrophils are largely
responsible for clearance of S. aureus from the bloodstream in animal infection models [69]. However,
neutrophils in suspension are relatively inefficient at phagocytosis, and published studies have shown
that blood-borne bacteria are largely cleared by phagocytes (neutrophils) in tissues such as the liver [70].
Importantly, phagocytosis of S. aureus by adherent human neutrophils—which are representative of
phagocytes at sites of infection—is highly efficient and seemingly unimpeded by anything produced by
the microbe [71,72]. The rapid ingestion of S. aureus by neutrophils was noted by Rogers and Tompsett
many years ago, and they also found that phagocytosis of S. aureus was significantly greater than that
of Klebsiella pneumoniae, group A streptococcus, or Streptococcus pneumoniae [69,73]. Therefore, the role
of S. aureus “antiphagocytic” molecules in the pathogenesis of human infections remains unclear. The
problem with S. aureus and human infections is not inefficient phagocytosis (David Rogers had an
interesting view on the topic [74]). Rather, a key issue is that some of the ingested bacteria are not
killed by the microbicidal systems that operate within the neutrophil phagosome [71,73,75,76]. These
ingested microbes ultimately cause lysis of neutrophils and, in turn, escape and disseminate [71,75,77].
3.3. Survival after Phagocytosis
S. aureus has the capacity to produce molecules that can moderate the cytotoxic effects of ROS and
AMPs. Survival of S. aureus inside the phagosome is directly linked to the ability to mitigate the effects
of host–derived ROS and AMPs. Superoxide dismutases (SodA and SodM), catalase (KatA), alkyl
hydroperoxide reductase (AhpCF), and staphyloxanthin (encoded by crtOPQMN), have been shown
to protect S. aureus from ROS [78–80]. S. aureus also mitigates the effects of ROS by means of proteins
and enzymes involved in metal ion homeostasis (reviewed by Cassat and Skaar [81]). Although these
systems moderate the bactericidal effects of ROS to some extent, it is well known that the NADPH
oxidase of phagocytes is essential for defense against S. aureus infections. Individuals with chronic
granulomatous disease, a disorder caused by inherited deficiency of one or more protein components
of NADPH oxidase, are highly susceptible to severe S. aureus infections in the absence of antibiotic
prophylaxis [82]. Most evidence to date indicates secondarily-derived ROS, such as HOCl produced
by the MPO-halide system (rather than superoxide or H2O2 directly), contribute to killing of ingested
S. aureus [83–85].
The dlt operon of S. aureus (dltABCD) encodes a cell envelope modification system that attaches
D-alanine to cell wall teichoic acids [86]. Incorporation of D-alanine into teichoic acids decreases
the negative charge on the bacterial surface and limits susceptibility of the microbe to cationic
AMPs, including human neutrophil alpha-defensins [86,87]. Collins et al. used a mouse infection
model to demonstrate that the dlt operon is important for S. aureus virulence [87]. Multiple
peptide resistance factor (MprF) of S. aureus transfers L–lysine to phosphatidylglycerol to produce
lysylphosphatidylglycerol, which contributes to neutralization of the negative charge of the bacterial
cell surface [88]. S. aureus strains with mprF genetically inactivated are significantly more susceptible to
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killing by human neutrophils, a phenomenon linked to increased binding to host AMPs [88]. S. aureus
mprF mutants also have a decreased virulence phenotype in mouse infection models, which further
underscores the importance of the resistance to AMPs in S. aureus pathogenesis [88]. In general,
DltABCD and MprF–mediated resistance to cationic AMPs works by charge neutralization—i.e.,
the AMPs no longer interact with the charge-neutral membrane of the microbe. There are several
other notable molecules and immune evasion systems utilized by S. aureus to promote survival after
phagocytosis by neutrophils. For example, lysozyme is a prominent antimicrobial agent present in
neutrophil granules. It functions as an antibacterial agent by hydrolyzing beta-glyosidic linkages in
cell wall peptidoglycan. Notably, S. aureus is completely resistant to lysozyme. This a characteristic
conferred by O-acetylation of peptidoglycan, a process catalyzed by a protein known as OatA [89].
3.4. Lysis after Phagocytosis
S. aureus is capable of producing an extensive arsenal of cytolytic toxins. Several of these molecules,
including alpha-type phenol soluble modulins (PSMα) [90], Panton-Valentine leukocidin (PVL) [91–93],
leukocidin GH (LukGH; also named leukocidin AB (LukAB)) [94,95], and gamma-hemolysin (Hlg) [96],
cause osmotic lysis of neutrophils. The role played by these molecules as secreted cytolysins in the
pathogenesis of S. aureus infections is an interesting topic, but outside of the scope of this review. Here
we focus our brief discussion on the contribution of molecules that contribute to lysis of neutrophils
after phagocytosis.
Rogers and colleagues discovered that S. aureus within granulocytes can be trafficked to tissues
and promote low-grade persistent infection [69,74]. This same phenomenon was reported many years
later by Gresham and colleagues using a mouse infection model [75]. Rogers and Tompsett were
among the first to show that S. aureus causes lysis of neutrophils after phagocytosis [73]. Voyich et al.
reported that prominent community-associated MRSA strains such as USA300 and USA400 have high
capacity to cause rapid lysis of human neutrophils after phagocytosis [71]. Recent work has shown that
LukGH/AB and PSMα to contribute to lysis of human neutrophils after phagocytosis [94,97]. However,
the contribution of these molecules is strain-dependent or partial, and therefore cannot explain the
phenomenon in full. Studies by Kobayashi et al. indicated that S. aureus—in this case USA300—is
contained within the phagosome to the point of neutrophil lysis [77]. The observed neutrophil lysis
was caspase and ROS-independent, findings incompatible with pyroptosis or NETosis [77]. Rather,
the authors suggested that lysis of neutrophils after phagocytosis of S. aureus is consistent with
programmed necrosis. Indeed, Greenlee-Wacker et al. then demonstrated that neutrophils undergo
programmed necrosis following phagocytosis of S. aureus [98]. Such cytolysis presumably contributes
to the pathogenesis of S. aureus infections, although direct evidence is still lacking and more work
is needed.
4. Conclusions
To summarize, S. aureus has capacity to produce many molecules directed to inhibit neutrophil
functions such as recruitment and phagocytosis. Despite this repertoire of immune evasion molecules,
severe invasive S. aureus disease is infrequent in otherwise healthy individuals who lack risk factors
for infection. In addition, the localized presence of neutrophils is a hallmark of S. aureus infections
and neutrophils readily phagocytose S. aureus. These observations bring into question the role of the
S. aureus immune evasion molecules in human disease (outside of the at-risk individual). Finally, the
possible utility of an opsonophagocytic vaccine for S. aureus is confounded by two key features of
S. aureus-neutrophil interactions: (1) phagocytosis is already efficient in the absence of a vaccine; and
(2) neutrophils can undergo rapid lysis after phagocytosis of S. aureus. Despite the noted caveats,
research in these areas must move forward. Advances in basic research that continue to elucidate
the complex interactions between S. aureus and the human host will likely offer new inroads into
developing more efficacious therapeutic treatments and perhaps, a preventative vaccine.
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